Experimental Ebola Drugs Cut Deaths In Congo, Study Finds : Goats and Soda Drugs tested in the Democratic Republic of Congo are effective in treating Ebola, scientists say. They have run a study in the midst of a deadly epidemic and in the face of armed assaults on doctors.
NPR logo

2 Experimental Ebola Drugs Saved Lives In Congo Outbreak

  • Download
  • <iframe src="https://www.npr.org/player/embed/750551040/750577783" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
2 Experimental Ebola Drugs Saved Lives In Congo Outbreak

2 Experimental Ebola Drugs Saved Lives In Congo Outbreak

  • Download
  • <iframe src="https://www.npr.org/player/embed/750551040/750577783" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

MARY LOUISE KELLY, HOST:

Researchers say they have identified the first clearly effective treatments for Ebola, a deadly disease that continues to spread in Central Africa. These drugs are experimental. They will be made widely available in the clinics treating Ebola patients. NPR science correspondent Richard Harris reports.

RICHARD HARRIS, BYLINE: Scientists in the Democratic Republic of Congo have been running a study in the midst of a deadly epidemic and in the face of armed assaults on doctors. They've been comparing four potential treatments to see whether any or all can hold the Ebola virus in check. Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says last week, researchers took a peek at the results and found that two of those treatments were markedly better.

ANTHONY FAUCI: We now have seen that there are at least two therapies that are showing a beneficial effect in prolonging the life or decreasing the mortality of Ebola virus disease. It certainly is not a total cure at all, but it clearly has shown a beneficial effect.

HARRIS: About half of all patients died when they took two of the four drugs. But for the other two medicines, mortality was about 30%. And people who got into treatment early did much better than that in the range of 10% mortality. There have been hints that another drug could help.

FAUCI: These two are certainly the first therapies that have clearly shown a beneficial effect.

HARRIS: They are both antibodies - biological drugs that help a person's immune system fight off infection. One was developed collaboratively with Fauci's institute and scientists in Africa. The other is made by the drug company Regeneron. The experimental treatments will now be made available to all Ebola patients who come to treatment centers in the DRC. More drug is being manufactured right now, Fauci says.

FAUCI: So this is not going to be a problem of drug supply.

HARRIS: Joining Fauci in announcing these findings were Dr. Jean-Jacques Muyembe from the DRC and Dr. Michael Ryan, who runs the World Health Organization's Health Emergencies Programme. Right now people are not coming in for treatment promptly, and that's a problem. First, Ryan says, people who delay treatment are less likely to survive.

MICHAEL RYAN: The second and very important consequence is that those patients spend longer amongst their family and friends and potentially expose other people in the community. So getting people into care more quickly is absolutely vital.

HARRIS: The challenge for doctors in the region is to convince people who are deeply suspicious of the treatment centers to leave their homes and seek that care.

RYAN: We are still seeing too many people staying away from Ebola treatment units, too many people not coming to hospital are not being found in time to benefit from these therapies.

HARRIS: And Dr. Muyembe from the DRC said he believes once communities learn there is an effective treatment, they will come to treatment centers promptly. That can only help end an epidemic that has already killed more than 1,800 people.

Richard Harris, NPR News.

(SOUNDBITE OF FALTYDL'S "ILL BENT")

Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.